CD122 (IL-2RB) Drug Discovery Landscape & Assay Solutions

Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Autoimmune Disease Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for CD122/IL-2RB drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen CD122 (IL2RB) ECD-Fc Fusion Protein
High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed.
View IL2RB Products
Gene Delivery IL2RB Promise-ORF / Lentivirus
Full-length human ORF for stable cell line generation. HEK293T packaged. Sequence Verified.
View IL2RB Products
Benchmark Ab Anti-CD122 (IL2RB) Reference Antibody
Recombinant positive control for binding, blocking, and occupancy assays.
View IL2RB Products
Validator IL2RB siRNA Set
For knockdown verification and target dependency controls.
View IL2RB Products
Co-receptor IL2RG (Common Gamma Chain)
Required for functional IL-2/IL-15 signaling complex. ECD-Fc available.
View IL2RG Products
Related Target IL2RA (CD25)
Alpha subunit of IL-2 receptor, defines high-affinity IL-2 signaling; key for Treg-sparing selectivity profiling.
View IL2RA Products
Related Target IL15RA
IL-15 specific receptor alpha, for competitive pathway analysis and IL-2/IL-15 selectivity.
View IL15RA Products

Critical Assay Challenges & TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Receptor Selectivity Profiling (CD122 vs CD25) and Heterodimeric Assembly (CD122 + CD132) Human / Cyno / Mouse CD122, CD25, CD132 ECD-Fc ortholog proteins available with >95% purity; sequence verified by mass spec.
IL-2 vs IL-15 Selectivity Screening Cross-species ortholog proteins and CD122/IL15RA dual-antigen panel for competition assays.
Treg vs Effector Cell Bias Validation High-concentration stability proteins for SPR/BLI affinity tuning and STAT5 phosphorylation assays.
Lack of Cross-Species Assay Controls Clinical Benchmark Antibodies and ortholog antigens included for rodent and NHP translation.
False Positives in Binding Assays Validated siRNA included for CD122-specificity checks and target dependency confirmation.

Live CD122 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for CD122-targeted therapeutics is intensifying, with major players shifting focus from traditional high-dose IL-2 to engineered cytokine muteins and CD122-biased agonists. As first-generation therapies (such as Roche's nemvaleukin alpha) advance through Phase 2 trials in combination with checkpoint inhibitors, the next wave of R&D is targeting differentiated receptor geometry—specifically bypassing IL-2Rα (CD25) to spare regulatory T cells while maximizing effector T-cell and NK-cell expansion. This evolution demands reagents that accurately model the heterodimeric CD122/CD132 interface and enable rigorous selectivity profiling against the trimeric IL-2 receptor complex. In autoimmune indications, biased agonism towards CD25/CD122 is explored to expand Tregs without systemic toxicity.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Engineered Cytokine (IL-2 Mutein, CD122-biased) Roche, Synthekine, Alkermes, Medicenna Solid Tumors (Ovarian, Renal), Melanoma Receptor Selectivity Assay (Need high-purity CD122 vs IL2RA proteins)
Anti-CD122 Antibody (Depleting/Agonist) Biotech Startups, Academia Autoimmune (Treg expansion), Transplantation Internalization Assay (Need stable CD122+ cell lines via Lentivirus)
Bispecific Cytokine / Immunocytokine Synthekine, Pfizer, Roche Immunotherapy combinations, Advanced Melanoma Heterodimer Validation (Need cross-reactive Abs for PK/PD and ortholog proteins)
Cell Therapy (CAR-T) Academic Institutions Hematologic Malignancies Expression Validation (Need CD122 Lentivirus for transduction)